297 results about "Rat model" patented technology

The invention belongs to the technical field of biomedical materials, and particularly relates to adipose-derived mesenchymal stem cell loaded conductive hydrogel and a preparation method and application thereof, the preparation method comprises the following steps: step S1, after hyaluronic acid is subjected to oxidation treatment, dopamine is grafted to oxidized hyaluronic acid, and oxidized hyaluronic acid-dopamine is obtained; step S2, carrying out amination treatment on gelatin to obtain aminated gelatin; s3, mixing the oxidized hyaluronic acid-dopamine with the aminated gelatin, and carrying out Schiff base crosslinking, so as to obtain hydrogel; and step S4, loading the adipose tissue-derived stromal cells by using the hydrogel. Dopamine is grafted on an oxidized hyaluronic acid macromolecular chain through amidation reaction, the hydrophilicity and the electrical property of the macromolecular chain are improved, a catechol structure is provided to provide possibility for iron ion coordination, the tissue adhesion, the injectability, the mechanical property and the electrical conductivity of the hydrogel are improved, and the hydrogel can be applied to the field of biomedical materials. After being applied to a spinal cord injury rat model, the functional recovery can be promoted.

The invention relates to the technical field of image recognition, in particular to an adhesion focus positioning method for an endometriosis rat model, which comprises the following steps of: firstly, adjusting a clustering distance according to color difference between saturation connected domains and a position inertial system, and clustering to obtain a connected domain cluster; due to the fact that the connected domain clusters contain the ectopic glands, the clusters need to be screened to obtain the ectopic glands, the gland probability of each connected domain cluster is obtained according to the characteristic that columnar epithelial cells are distributed on the inner walls of the ectopic glands, and the possibility that each connected domain cluster belongs to the ectopic glands is judged; due to the fact that the ectopic glands are distributed in a concentrated mode, the abnormal probability of the connected domain clusters is obtained through the aggregation of the connected domain clusters with the high gland probability, the possibility that the connected domain clusters belong to the abnormal ectopic glands is further judged, and the focus positioning accuracy of the endometriosis rat model is higher.

The invention discloses a stem cell exosome based on targeted fusion polypeptide modification, a preparation method and application of the stem cell exosome in treating male erectile dysfunction. According to the exosome, a specific targeting fusion polypeptide (sequence: EPLQLKM-GGGS-DPPV) is anchored on the surface through a chemical coupling technology, so that the targeting property of the exosome on cavernosum smooth muscle cells is enhanced; meanwhile, an anti-TrkA monoclonal antibody (TrkA-2E7-HL) is loaded through an electroporation method, and a fibrosis pathway mediated by a nerve growth factor (NGF) is inhibited. The exosome induces secretion of the umbilical cord mesenchymal stem cells by adopting an anti-oxidation culture medium, so that the anti-oxidation activity of the exosome is remarkably improved. Experiments show that in a diabetes ED rat model, the erectile function (ICP / MAP ratio) of the modified exosome is improved to 0.79 + / -0.05, the fibrosis area is reduced to 9.2 + / -1.6%, and the NO secretion level is improved by 3.5 times compared with that of a common exosome. Through triple mechanisms of polypeptide targeting, antibody synergy and oxidation resistance, effective reversion of the ED pathological process is realized, and the polypeptide has remarkable novelty and clinical transformation potential.

The invention belongs to the technical field of biology, and particularly relates to casein phosphopeptides for promoting absorption of calcium, iron and zinc minerals and improving bone health. Casein phosphopeptides containing high-activity peptide fragments are obtained through an optimization process, six mineral elements of calcium, magnesium, copper, iron, zinc and manganese serve as research objects, firstly, mineral utilization of CPP is evaluated through a mineral deficiency rat model, the content of Ca, Mg, Cu, Fe, Zn and Mn in thighbones is increased by 7.12%, 3.56%, 20.76%, 15.84%, 9.94% and 67.12% respectively when the CPP is eaten by 7mg / kg.d; secondly, screening a peptide fragment with calcium absorption promoting activity from the CPP by utilizing a molecular docking technology, and performing functional verification; the invention aims to reveal the action effect of CPP in mineral absorption and utilization from cell and animal levels, and provides a theoretical basis for functional development of CPP.

The invention discloses a biomarker related to diabetic neuralgia and application of the biomarker. The biomarker is IGFBPs or CD324. According to the application, a DNP (Diabetic Neuralgia) rat model is constructed, the DIA and DDA combined technology is adopted, DNP model rats are subjected to serum proteome detection, and through analysis, screening and verification, compared with normal group rats, the expression level of IGFBPs or CD324 in serum of the DNP model rats has significant difference; according to the method, IGFBPs or CD324 is taken as a biomarker, a working characteristic curve (ROC) of a subject is drawn at the same time, and IGFBPs or CD324 is evaluated according to area under the curve (AUC) to have excellent diagnostic efficiency when applied to diabetic neuralgia as the biomarker, so that a new biomarker can be provided for auxiliary diagnosis of diabetic neuralgia, and clinical diagnosis of diabetic neuralgia is more convenient and accurate.

The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with Met in preparation of anti-diabetic drugs. The diabetes mellitus is particularly type 2 diabetes mellitus. Through construction of a T2DM rat model, paraffin tissue section detection, serum ELISA, cell experiments and the like, researches prove that T2DM can be effectively treated by HUC-MSCs combined with Met treatment, including reduction of body blood sugar and recovery of blood sugar regulation ability; liver injury caused by T2DM is relieved and repaired; the glycolipid metabolism of the liver of the T2DM rat is improved; the immune inflammation disorder caused by T2DM is relieved; and the apoptosis level of liver cells is improved. And compared with a single hUC-MSCs or Met treatment mode, the combined treatment mode has a better treatment effect. The invention provides a theoretical basis and a new treatment strategy for treatment of T2DM.

The invention relates to the technical field of biology and new medicine, in particular to a preparation method, an identification method and a histopathologic analysis method of a rat uterus scar diverticulum model. The preparation method of the rat uterus scar diverticulum model comprises the following steps: sequentially simulating rat pregnancy by using female progestational hormone, and infecting a uterus incision by using group B streptococcus (GBS) to obtain the rat uterus scar diverticulum model. The preparation method comprises the following steps: constructing a pseudopregnant rat model; preparing a GBS bacterial solution with a certain concentration, and immersing 3-0 silk threads with the length of about 1cm into the bacterial solution for 24 hours for later use; an incision with the length of about 2 cm is formed in the uterus on the two sides of the rat, and the incision is sutured discontinuously by an absorbable line. The simulated pregnant mouse is used, the influence of uterine hyperemia during human delivery and hormone change after female progestational hormone withdrawal on the uterine microenvironment is met, the formation of the human uterine scar diverticulum simulated by using the group B streptococcus infection incision is related to cesarean delivery incision infection, and therefore the success rate of the obtained model is high.

The invention discloses a method for constructing a polycystic ovarian syndrome (PCOS) rat model with reduced sex hormone binding globulin (SHBG) on the basis of ruminococcus aureus with the preservation number of ATCC29149, and belongs to the technical field of animal models. According to the present invention, the bacterial strain is subjected to anaerobic culture to prepare the bacterial liquid, the dosage is 0.2-1 mL / 100 g, the intragastric administration frequency is one time per day to two times per week, and the time lasts for 4-8 weeks, such that the SHBG synthesis of the rat liver is induced to decrease, and the PCOS pathological characteristics such as testosterone level increase, estrus cycle disorder, ovarian polycystic change, insulin resistance and the like are initiated; the problem that a traditional hormone induction method does not conform to the physiological status is solved, the modeling period of a high-fat diet induction method is shortened, and an efficient experimental tool is provided for PCOS mechanism research and drug development.

The invention discloses application of sodium butyrate in preparation of a medicine for relieving brain injury caused by gas explosion, the sodium butyrate regulates nerve cell ferroptosis through a JNK / P38 MAPK pathway to relieve the brain injury caused by gas explosion, firstly, an animal model of rat brain injury caused by gas explosion is established, and the relation between NaB and brain tissue neuron injury is intervened and observed by applying NaB; secondly, a shock wave physiotherapy instrument is used for impacting a co-culture system of three cells of CTX, H19-7 and GMI-R to simulate explosion to construct an in-vitro experimental model, P38, ERK and Fer-1 inhibitors are adopted for intervention, iron metabolism, ferroptosis and MAPK signal channel factor changes are observed from the cell and molecular level, a mechanism for inhibiting ferroptosis through a related cascade signal channel mediated by NaB-mediated intestinal-brain axis regulation and control is clarified, and the effect of inhibiting ferroptosis is achieved. And a theoretical basis is provided for further explaining the action mechanism of the gas explosion brain injury.

The invention belongs to the technical field of biology, and particularly relates to casein source heptapeptide for promoting calcium absorption and utilization and application of the casein source heptapeptide. The CPP containing the high-activity peptide fragment is obtained through an optimization process, and the influence of the CPP on mineral absorption and conversion is evaluated by utilizing a mineral deficiency rat model; then, heptapeptide with calcium absorption promoting activity is screened out from the CPP in combination with peptiomics and molecular docking technologies, functional verification is carried out, it is found that when the VAPFPEV is 2 mu M, the Ca < 2 + > transport amount is remarkably increased by 25.25%, meanwhile, zebra fish experiments show that intervention of the VAPFPEV effectively reverses reduction of an accumulated optical density value caused by dexamethasone, and compared with a module making set, the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the The skull accumulative optical density value of a VAPFPEV (1-20 [mu] M) processing group is obviously increased. It is shown that VAPFPEV can effectively promote Ca < 2 + > transfer and absorption, improve the osteoporosis symptom of zebra fish and increase deposition of calcium in bones.

The invention relates to an N-acetyl-D-glucosamine composition with an anti-tumor effect and application of the N-acetyl-D-glucosamine composition, and relates to the technical field of medicines and health care products, the N-acetyl-D-glucosamine composition with the anti-tumor effect comprises the following raw materials by weight: 17-29 parts of N-acetyl-D-glucosamine and 5-10 parts of an extract of Tongshan. According to the invention, the N-acetyl-D-glucosamine and the extract in a proper proportion are matched for use for the first time, so that the synergistic interaction of the N-acetyl-D-glucosamine and the extract is realized. In-vitro animal anti-tumor experiments show that the N-acetyl-D-glucosamine composition provided by the invention can significantly reduce the tumor volume in a rat model, provides a new way for clinical treatment of tumor patients, and has a wide application prospect.

The invention discloses a construction method and application of a Keman ataxia rat model, and belongs to the technical field of animal models. The construction method of the Keman ataxia rat model comprises the step of mutating the 38th nucleotide of the ATCAY gene exon 3 of a rat from G to A. The constructed Kemann ataxia rat model provides a research mode tool for researching the function of the ATCAY gene in Kemann ataxia and screening or preparing medicines for preventing or treating Kemann ataxia.

The invention discloses a polylipoic acid-based elastic patch capable of inducing adhesion in a wet environment as well as a preparation method and application of the polylipoic acid-based elastic patch. The polylipoic acid-based elastic adhesion patch can be obtained by simply concentrating and evaporating a mixed solution of lipoic acid and methacrylated gelatin. Due to the introduction of a methacrylated gelatin polymer chain, the layered crystal structure of an original lipoic acid-based polymer is reduced, so that the water sensitivity of the lipoic acid-based polymer is reduced, the release time of lipoic acid active molecules is prolonged, and a small amount of layered crystal structures are reserved in the polylipoic acid-based elastic adhesion patch; therefore, non-adhesion and rigidity are realized in a dry environment. Once exposed to water or body fluid, the hydrophilic polymer backbone of the patch can quickly absorb moisture, the entry of water molecules destroys the layered crystal structure, resulting in softness and adhesion of the patch. In a rat model with ligation of periodontitis, the patch can effectively relieve inflammation and inhibit alveolar bone resorption.

The invention discloses a noninvasive chronic abacterial prostatitis rat model making device which comprises a multifunctional operation base, a lifting stand column, a rat posture adjusting mechanism, a rat fixing plate, a lifting support, a pitching angle adjusting mechanism and a rat prostate multi-mode stimulator. The lifting support is fixed on the base, the pitching angle adjusting mechanism is fixed on the lifting support, the rat prostate multi-mode stimulator is fixed on the pitching angle adjusting mechanism, the rat posture adjusting mechanism is fixed on the multifunctional operation base, and the rat fixing plate is fixed on the rat posture adjusting mechanism. According to the device, the chronic abacterial prostatitis rat model is constructed by combining prostate local thermal stimulation with prostate local high-frequency vibration stimulation, the prostate tissue of the rat is noninvasive in the whole modeling process, and the problem of modeling failure or low success rate caused by introduction of bacteria in the injection puncture process is avoided.

The invention provides a pharmaceutical composition and application thereof in preparation of a compound preparation, and belongs to the field of medicines. The pharmaceutical composition comprises a potassium ion channel opener, a 5 alpha-reductase inhibitor and a phosphodiesterase 5 inhibitor. The pharmaceutical composition can synergistically promote treatment of androgen dependent diseases or prevention of complications, and by taking the pharmaceutical composition of minoxidil, finasteride and tadalafil as an example, the effects in a benign prostatic hyperplasia rat model and an androgenic alopecia mouse model are verified, which indicates that the minoxidil, finasteride and tadalafil have a synergistic interaction effect, and the pharmaceutical composition can be used for treating the androgen dependent diseases or preventing the complications. Good clinical application prospects are realized.

The invention discloses an application of 4-octyl itaconic acid (4-OI) in preparation of a medicine for improving pulmonary arterial hypertension (PAH). In-vivo experiments show that 4-OI can significantly reduce pulmonary vascular wall thickening and collagen deposition of a PAH rat model, and effectively improve PAH and vascular remodeling. In-vitro experiments further reveal that 4-OI reduces endoplasmic reticulum stress (ERS) by inhibiting a PERK-eIF2alpha pathway, further blocks SM22 dependent smooth muscle cell phenotypic transformation and endothelial-mesenchymal transformation (EndMT) processes, finally inhibits vascular remodeling, and plays a role in treating PAH. The three key pathological processes of ERS, EndMT and vascular remodeling are closely linked, a new perspective is provided for deeply understanding the correlation among oxidative stress, endothelial dysfunction and vascular structure change in PAH, meanwhile, a theoretical foundation is laid for developing PAH and vascular remodeling accurate treatment drugs, and clinical transformation value is achieved.

The invention discloses a polypeptide with blood pressure lowering and oxidation resisting effects as well as a related product and application thereof, and relates to the technical field of biology. According to the invention, casein is taken as a raw material, and the milk-derived active peptide ALPQY is successfully obtained through multi-enzyme hydrolysis, separation, purification and identification. In-vitro activity evaluation results show that the polypeptide not only has strong ACE inhibitory activity, but also can effectively scavenge free radicals; the ACE inhibition IC50 value is 35.56 mu M, the free radical scavenging TEAC value is 1.83 mu mol TE / mu mol, and compared with similar polypeptides, the polypeptide has better ACE inhibition effect and free radical scavenging effect. In-vivo antihypertensive evaluation is carried out through a spontaneous hypertension rat model, it is also shown that the compound has a good antihypertensive effect, and the compound can be used for preparing products related to antihypertensive and / or antioxidation.

The invention relates to an application of a THBS4 inhibitor in preparation of a medicine for preventing and / or treating pulmonary arterial hypertension. Three pulmonary arterial hypertension rat models (a hypoxia induction model, a hypoxia combined SUGEN induction model and a monocrotaline induction model) are constructed, the expression change of THBS4 is verified through qRT-PCR and western blot, and the correlation between the expression level of THBS4 and pulmonary arterial hypertension is verified in combination with in-vitro cell experiments and in-vivo intervention. Results show that THBS4 is remarkably up-regulated in pulmonary arteries of the three models, the expression level of THBS4 is positively correlated with the severity of diseases, and THBS4 is an important regulatory factor for promoting vascular remodeling in pulmonary arterial hypertension. In vivo, by knocking down THBS4, pulmonary vascular remodeling and right ventricular hypertrophy are remarkably relieved, and it is prompted that THBS4 inhibitors show good application prospects in the aspect of preventing and / or treating pulmonary arterial hypertension.

The present application relates to the field of model construction, in particular to a kind of construction method of vertebral artery compression rat model, the inner diameter and blood flow velocity of normal rat vertebral artery are obtained by ultrasonic detection;Anesthetize rat, skin preparation, disinfection, incision, expose vertebral artery;According to the required compression degree, select the tissue clip of corresponding specification, fix on vertebral artery, keep vertebral artery in compression state;Suture incision, disinfection, bandage;After rat awakens, daily care, feed, until incision healing;Ultrasonic detection is carried out, the inner diameter and blood flow velocity of the vertebral artery of rat model are obtained, compared with the inner diameter and blood flow velocity of the vertebral artery of the same age healthy rat or rat before modeling, whether it meets the standard of successful modeling is judged.

The invention relates to a colla corii asini-concha haliotidis compound as well as a preparation method and application thereof, and belongs to the technical field of medicines and health-care products. The colla corii asini-concha haliotidis compound provided by the invention comprises the following components in parts by weight: a) 38-42 parts of colla corii asini; b) 15-25 parts of concha haliotidis; and c) 1-5 parts of an auxiliary material, wherein the auxiliary material is selected from one or more of polyvinylpyrrolidone, copovidone, hydroxy propyl cellulose and hydroxyethyl cellulose. The donkey-hide gelatin and concha haliotidis compound is prepared by using a hot melt extrusion technology, so that the smell, wettability, dispersity and other properties of the donkey-hide gelatin are obviously improved, and the donkey-hide gelatin compound shows a good effect in an osteoporosis rat model and a calcium-deficient mouse model. The preparation process is simple and controllable, and has a good market prospect.

The invention belongs to the technical field of biomedicine, and particularly relates to an animal model and a modeling method thereof. According to the method, the northwest dryness syndrome type sub-health animal model is successfully constructed, an open model evaluation mode is adopted, and the established model is evaluated through goodness of fit; furthermore, autumn pear syrup is used for indicating that the prescription corresponds to the syndrome. The northwest dryness syndrome type sub-health target model established by the invention can provide a stable and reliable research model for external dryness syndrome essence exploration, arid region sub-health prevention and treatment, drug effect and pharmacological mechanism research of traditional Chinese medicines, prescriptions and the like with body resistance strengthening and dryness moistening effects, health product research and development and the like. An open model evaluation mode is adopted, and the higher the goodness of fit is, the closer the model to the northwest dryness syndrome type sub-health target model is. The northwest dryness syndrome type square domain dryness evil sub-health rat model is more suitable for arid region sub-health status research, and the northwest dryness syndrome type autumn cause dryness evil sub-health rat model is more suitable for autumn moistening health care research.

The invention discloses an NLRP3 inhibitor as well as a preparation method and application thereof. Specifically, the invention relates to a compound shown as a formula (NLRP3i-3) or a pharmaceutically acceptable salt thereof, the formula (I) is COCCNc1nc2c (c (= O) n (C) c (= O) n2C) n1Cc1cc (OC) ccc1N, and the chemical name is 8-((4-amino-2-methoxybenzyl)-7, 9-dimethyl-7, 9-dihydro-8H-purine-6, 8-diketone. The invention also provides a preparation method of the compound, a pharmaceutical composition containing the compound, and application of the compound in preparation of drugs for preventing and / or treating NLRP3-mediated diseases. The disease is preferably myocardial ischemia reperfusion injury. Experimental results show that the compound provided by the invention has excellent NLRP3 inhibitory activity (IC50lt, 100nM), and has high selectivity to NLRP3 inflammasomes; good pharmacokinetic characteristics are achieved in a rat body, and the bioavailability is high; in myocardial ischemia reperfusion injury models of mice and rats, the composition can significantly reduce myocardial infarction area, reduce myocardial enzyme level, alleviate inflammatory response and improve heart function; preliminary toxicological evaluation shows that the safety is good. Therefore, the compound disclosed by the invention is expected to be developed into a novel medicine for treating NLRP3 related diseases such as myocardial ischemia-reperfusion injury.

The invention discloses application of an HIF1A inhibitor in preparation of a medicine for preventing and / or treating hypertrophic cardiomyopathy, and belongs to the field of biological medicine. For a rat model of spontaneous hypertrophic cardiomyopathy caused by MYH7B gene knockout, hypertrophic cardiomyopathy can be significantly relieved by intraperitoneal injection of the HIF1A inhibitor LW6, heart remodeling can be relieved, heart functions can be improved, and myocardial hypertrophy caused by silent MYH7B genes can be effectively resisted by using siRNA of mRNA transcribed by the HIF1A gene. The key mechanism of the HIF1A inhibitor for treating the hypertrophic cardiomyopathy is that the hypertrophic cardiomyopathy is prevented and treated by reducing the expression level of glycolysis key enzymes GLUT1, HK2 and the like, inhibiting the formation and accumulation of cardiac lactic acid and improving the ventricular remodeling of the hypertrophic cardiomyopathy. The results show that the HIF1A inhibitor can be used for treating and / or preventing the human hypertrophic cardiomyopathy and has the potential of being developed into the medicine for clinically preventing and treating the hypertrophic cardiomyopathy.

The invention discloses a vagus nerve electrical stimulation regulation method capable of relieving ARDS lung injury, and relates to the technical field of ARDS lung injury. In order to improve the therapeutic effect and prognosis of ARDS patients; comprising the following steps that 1, an ARDS animal model is established, and the animal model is constructed by instilling lipopolysaccharide (LPS) into the trachea; 2, after the ARDS model is established, separating and exposing the left vagus nerve of the animal; and 3, performing electrical stimulation on the left vagus nerve by using an electrical stimulation device, wherein the stimulation parameters comprise the voltage of 5V, the frequency of 5Hz and the pulse width of 2ms, and the stimulation lasts for 10 minutes. By implementing a vagus nerve electrical stimulation (VNS) regulation method, lung tissue pathological changes of an ARDS rat model can be remarkably improved, such as alveolar wall thickening, alveolar cavity stenosis and inflammatory cell infiltration, the lung injury score and the lung moisture-to-dry ratio are remarkably reduced, and the pulmonary edema condition is effectively relieved.

The application relates to a method for constructing a rat model of chronic obstructive pulmonary disease (COPD) related pulmonary arterial hypertension and application thereof, and belongs to the technical field of animal disease model construction. The method selects 6-8-week-old, 220+ / -10g healthy male SD rats, and all the rats are adaptively fed in a standard SPF level animal room for 7 days; then the rats are divided into a Con group and a COPD-PH group; the rats in the COPD-PH group are given 1mg / mL lipopolysaccharide by airway instillation on the first day and the 14th day; the rats are placed in a self-made whole-body inhalation smoking box for 1h every day from the 2nd day to the 13th day and from the 15th day to the 30th day; the rats enter a low-oxygen box for 8h every day during the light period from the 2nd day to the 13th day and from the 15th day to the 30th day; the rat model can simultaneously reproduce the characteristics of COPD and typical changes of pulmonary arterial hypertension, the right ventricular systolic pressure can be stably increased to 40-50mmHg, the right ventricular hypertrophy index can reach 0.40-0.50, the pulmonary vascular remodeling and inflammation are significant, and various indexes are stable and good in repeatability.

The invention discloses an application of N6022 in improving brain injury after cardiac arrest resuscitation, and particularly relates to an application of N6022 or a derivative thereof given through a nose in improving the brain injury after cardiac arrest resuscitation and increasing the survival rate after cardiac arrest resuscitation. Compared with the prior art, the application has the advantages that the increased GSNOR enzyme activity of brain tissues after sudden cardiac arrest resuscitation can be effectively inhibited by nasal injection of N6022 into a sudden cardiac arrest resuscitation rat model; the N6022 can effectively improve the neurological function after cardiac arrest resuscitation and increase the survival rate after cardio-pulmonary resuscitation; n6022 is used for inhibiting the activity of GSNOR, so that the number of survival neurons of brain tissues after sudden cardiac arrest resuscitation can be increased; the delivery mode of the N6022 through the nose can effectively enable the N6022 to enter the brain tissue of the rat. According to the invention, a new application field of N6022 is developed, and a meaningful reference is provided for improving the cerebral function after sudden cardiac arrest resuscitation.

The invention belongs to the technical field of biological medicine, and relates to application of miRNA targeted regulation in treatment of acute respiratory distress syndrome, in particular to application of a miR-144 inhibitor in preparation of a medicine for improving glucocorticoid treatment sensitivity of an ARDS patient. Research on a lipopolysaccharide-induced ARDS rat model finds that miR-144 participates in regulation and control of glucocorticoid receptor beta (GR beta) and NF-kappa B signal pathways in the ARDS inflammatory reaction process, the number of neutrophils in alveolar lavage fluid and the level of inflammatory factors such as IL-6 and TNF-alpha can be remarkably reduced by using the miR-144 inhibitor and glucocorticoid for treatment, and the application of the miR-144 inhibitor to treatment of the pulmonary alveolar lavage fluid in the treatment of the pulmonary alveolar lavage fluid is broad. The wet-to-dry ratio and pathological injury score of lung tissues are reduced, and GR beta and NF-kappa B expression is inhibited, so that the anti-inflammatory effect of glucocorticoid is remarkably enhanced. The invention provides a treatment strategy for improving glucocorticoid resistance of ARDS patients by taking miR-144 as a target for the first time, and provides a new drug target and a technical scheme for accurate treatment of ARDS.

The invention discloses an application of daidzin to preparation of a medicine and a potency verification method of daidzin, the medicine is applied to improvement of age-related macular degeneration, and the potency verification method comprises in-vitro verification and in-vivo verification; the protection effect of daidzin on oxidative damage caused by SIN-1 is evaluated through an in-vitro experiment, and the protection effect is specifically shown as increase of cell activity and reduction of MDA content; in-vivo verification is completed by means of a rat model, a visual placement reaction experiment is formed, a rat visual function system is evaluated, the MDA content of rat eye peripheral blood is detected, and it is clear that the daidzin can obviously relieve AMD damage, that is, the daidzin has an obvious improvement effect on AMD; and daidzin is good in safety and low in improvement and treatment cost on age-related macular degeneration, and meets the current clinical requirements.

The invention provides a manufacturing method of a silica-induced lung injury rat model and application of Erchen decoction. A manufacturing method of a silica-induced lung injury rat model is used for researching medical application and pathological effects of Erchen decoction in treatment of silicosis, traditional Chinese medicines in the Erchen decoction comprise Pinellia ternate, dried orange peel, Poria cocos, honey-fried licorice root, dark plum and ginger, and the manufacturing method is characterized by comprising the following steps: S1, experimental animals and grouping; the invention provides a manufacturing method of a silica-induced lung injury rat model and an application of Erchen soup, and systematically verifies and deepens a microecological mechanism of silicosis on the basis of early discovery; a new accurate diagnosis and treatment target is provided; the modern breakthrough of pharmacological research of traditional Chinese medicines is realized; the dysbacteriosis type silicosis model established by the invention has the advantages of simple and convenient modeling method, good repeatability, clear pathological characteristics and clear key target spots.

The invention provides a construction method and application of a liver-heat rat model, and relates to the technical field of medical animal experiment models.The construction method comprises the steps that adult rats are placed in a humid and hot environment with the temperature being 30 + / -2 DEG C and the humidity being 75 + / -5%, fed with high-fat feed, drunk with beer instead of water every day and subjected to gavage with baijiu twice every week, and the adult rats are totally fed for 12-16 weeks; and performing liver heat syndrome scoring and liver heat disease scoring on the rats obtained by feeding, and when the sum of the liver heat syndrome scores and the sum of the liver heat disease scores are both greater than or equal to a preset standard score, obtaining the liver heat rat model. According to the method, a disease modeling factor and syndrome modeling factor superposition method is adopted to establish a disease and syndrome combined'liver heat 'rat model, establishment of each syndrome macroscopic characterization index quantitative evaluation system is reasonably proposed, corresponding microscopic indexes are introduced to macroscopic characterization, and traditional Chinese medicine innovative research on liver disease prevention and treatment can be assisted.